Action BIO.B BIO-RAD LABORATORIES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Bio-Rad Laboratories, Inc. Nyse

Actions

BIO.B

US0905721082

Marché Fermé - Nyse
Autres places de cotation
 22:15:00 17/07/2024 		Varia. 5j. Varia. 1 janv.
283,5 USD 0,00 % Graphique intraday de Bio-Rad Laboratories, Inc. 0,00 % -11,60 %
06/06 Transcript : Bio-Rad Laboratories, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 10:30 AM
30/05 Bio-Rad Laboratories, Inc. nomme Anette Engelhardt au poste de vice-présidente exécutive et présidente du groupe de diagnostic clinique, à compter du 10 juin 2024. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
Bio-Rad Laboratories, Inc.(NYSE:BIO) added to Russell 2500 Value Index
Bio-Rad Laboratories, Inc.(NYSE:BIO) added to Russell 2500 Index
OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.
OncoCyte's (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $2.29, vs. Street Est of $2.14
Bio-Rad: Q1 Earnings Snapshot
Bio-Rad Reports First-Quarter 2024 Financial Results
Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023.
Bio-Rad's Management to Participate in Fireside Chat during RBC Capital Markets Global Healthcare Conference
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
Bio-Rad Announces Life Science Group Management Changes
Bio-Rad Announces Life Science Group Management Changes
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BIO
  4. Action BIO.B
  5. Actualités Bio-Rad Laboratories, Inc.
  6. Autres langues